A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of NNC0385-0434 to Healthy Male Participants - Oral Formulation II
Latest Information Update: 22 Jul 2024
At a glance
- Drugs NNC0385 0434 (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 14 Nov 2022 Status changed from recruiting to completed.
- 04 Aug 2022 Planned End Date changed from 19 Sep 2022 to 21 Sep 2022.
- 04 Aug 2022 Planned primary completion date changed from 30 Jun 2022 to 21 Sep 2022.